The Therapeutic Vaccine Potential of MIS416 Adjuvant - Linking innate and adaptive immunity through the activation of multiple innate host defenses. - BioPharm International
Figure 5. MIS416 therapy suppresses weight loss and mortality after infection with type A influenza. (A) C57BL/6 mice (n
= 10 per group) were infected with 0.3 LD-50 influenza A strain A/PR/8/34 (H1N1). The following day, animals received vehicle
control (saline), 50 µg MIS416, or 250 µg of MIS416 intravenously. Weights were monitored daily. Where indicated (*), MIS416
therapy significantly reduced weight loss. (B) Mice were infected as described above. Animals that lost more than 30% of their
initial weight were considered moribund and euthanized. Data are pooled from two independent experiments (n = 15 total mice
per group). The reduced morbidity of animals treated with MIS416 was statistically significant (p = 0.035 by Log rank test).
Figure 6. Enhancement of purified human NK spontaneous killing activity following stimulation with MIS416. Human CD56+ cells
were purified from whole blood to 99% and cultured for 40 hours with no stimulus, known NK activating agents IL-2 (500 U/mL)
and IL-12 (50 ng/mL) or with MIS416 (40, 20, 10, and 5 µg/mL). Stimulated NK cells were subsequently tested for cytotoxicity
against fluorescently labelled NK sensitive K562 tumor targets at effector:target ratios of 5:1, 2:1, and 1:1. Tumor cell
killing was determined after four hours by flow cytometric analysis of viability dye uptake (propidium iodide) of gated, fluorescent
K562 targets.
Therapeutic vaccines administered to cancer patients are designed to treat cancer by stimulating the immune system to recognize
and attack human cancer cells without harming normal cells, and to overcome the immune system's tolerance to cancer antigens.
